Coreg: adverse event reports filed with FDA

4,989

reports as suspect product

0% of all reports · about 222 a year

29

reports, 12 months to June 2026

27 in the 12 months before

41.4%

marked serious by the reporter

76.2% across the class

4.8%

record death among outcomes, as reported

237 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Coreg reports recording the termmedian drug in alpha-adrenergic blocker

1. Dizzinesslight-headedness or unsteadiness13%651
2. Fatiguetiredness11%551
3. Dyspnoeashortness of breath9.7%486
4. Hypotensionlow blood pressure7.1%355
5. Drug ineffectivethe medicine did not work as expected6.9%346
6. Astheniaweakness or lack of energy6.1%302
7. Nauseafeeling sick4.4%220
8. Headachehead pain4.2%211
9. Blood pressure increaseda raised blood pressure reading3.7%184
10. Weight increasedweight gain3.5%174
11. Drug hypersensitivityan allergic-type reaction to a medicine3.3%167
12. Coughcough3.1%155
13. Diarrhoealoose or frequent stools3.1%155
14. Blood pressure decreaseda low blood pressure reading3.1%154
15. Malaisegeneral feeling of being unwell2.9%145
16. Cardiac failure congestivecongestive heart failure2.8%138
17. Hypertensionhigh blood pressure2.8%138
18. Chest painchest pain2.6%131
19. Feeling abnormalfeeling odd or not right2.6%131
20. Rashskin rash2.6%130
21. Heart rate decreased2.6%129
22. Blood glucose increasedraised blood sugar reading2.5%125
23. Insomniadifficulty sleeping2.5%124
24. Falla fall2.4%119
25. Deaththe patient died; cause not stated by this term2.3%117
26. Weight decreasedweight loss2.3%116
27. Heart rate increaseda fast heart rate reading2.3%115
28. Palpitationsawareness of the heartbeat2.3%114
29. Syncopefainting2.3%113
30. Alopeciahair loss2.2%112

Top 30 of 778 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 12 drugs in the alpha-adrenergic blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 38,454 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 92.9% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,989 reports.

Drugs most often listed in the same reports

Other products listed in reports where Coreg is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the alpha-adrenergic blocker class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Coreg as a suspect or interacting product; reports listing it only as a concomitant medication (32,439) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.